Loading stock data…
ARWR
$76.39+1.58 (+2.11%)
Market ClosedLast close May 4
Arrowhead Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arrowhead Pharmaceuticals, Inc. in the Healthcare sector is trading at $76.39. The stock is currently near its 52-week high of $76.76, remaining 56.3% above its 200-day moving average. Technical signals show neutral RSI of 70 and bullish MACD crossover, explaining why ARWR maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 70) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$76.39
Potential Downside
45.6%
Whystock Fair Value$41.53
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Buy
Mean target$84.50+10.6%
Range$35.00 – $110.00
Fundamentals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of ang...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
46.20
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.27
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
35.58%
Volume
Today's trading volume
1.47M
Recent News
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Australian Approval Of REDEMPLO For FCS
Arrowhead Pharmaceuticals’ REDEMPLO (plozasiran), a small interfering RNA therapy, was recently approved by Australia’s Therapeutic Goods Administration as the first and only medicine to reduce triglyceride levels in adults with familial chylomicronemia syndrome when standard treatments are inadequate. This latest approval, backed by the PALISADE Phase 3 data showing very large median triglyceride reductions and fewer acute pancreatitis events, further extends REDEMPLO’s global footprint...
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s obesity and metabolic illness initiatives, TD Cowen reiterated its Buy rating on March 26. The firm pointed out that Wave Life Sciences published more data from Arrowhead’s ARO-INHBE program, demonstrating that, despite the higher […]
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings
The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.
This Biotech Stock Is Up 460% Over the Past Year. Why Analysts See It Rising Higher.
Shares of Arrowhead Pharmaceuticals have soared 460% over the past year, far eclipsing the broader market. Morgan Stanley analyst Michael Ulz is eagerly awaiting the release of Phase 3 study data in the third quarter, which he expects to “unlock a multibillion-dollar opportunity that remains underappreciated.” The vote of confidence came as Ulz upgraded Arrowhead stock to Overweight from Equal-weight with a $100 price target, up from $78.
Intel upgraded, Reddit initiated: Wall Street's top analyst calls
Intel upgraded, Reddit initiated: Wall Street's top analyst calls